Introduction
============

The emergence of β-lactam resistance in *Escherichia coli* which is the most common cause of Gram-negative infections has become a significant health concern, mainly due to the production of extended-spectrum beta-lactamases (ESBLs) ([@B27]). Indeed, CTX-M ESBLs (more than 150 enzymes) have increased significantly in *Enterobacteriaceae*, particularly in *E. coli*, in most regions of the world ([@B11]). Another worrisome feature is the emergence of isolates resistant to all clinically important aminoglycosides related to the production of 16S rRNA methylases. In 2003, the first 16S rRNA methylase gene, *armA*, was identified ([@B16]). To date eleven 16S rRNA methylases genes (*rmtA*, *rmtB*, *rmtC*, *rmtD*, *rmtD2*, *rmtE*, *rmtF*, *rmtG*, *rmtH*, *armA*, and *npmA*) have been identified, *armA* and *rmtB* being the most frequently described in *Enterobacteriaceae* ([@B16]; [@B9]; [@B35]; [@B15]). As these genes are usually located on plasmids they can easily transfer to other bacteria ([@B25]).

In Algeria, the first CTX-M enzymes have been reported in 2005 in clinical strains of *Salmonella enterica* from Constantine, East of Algeria ([@B24]). Since then, several surveys in the north of Algeria have reported the presence of CTX-M-type enzyme and associated resistance to non-β-lactam markers in various species of *Enterobacteriaceae* ([@B1]). Concerning 16S rRNA methylases only ArmA has been detected to date. It was identified for the first time in *Enterobacteriaceae* strains isolated from an Algerian patient transferred to Belgium ([@B9]). It was subsequently identified in clinical isolates of *S. enterica* in Constantine associated with CTX-M-3 or CTX-M-15 ([@B23], [@B22]) and in clinical strains of *Salmonella* non-Typhi in Annaba associated with CTX-M-15 and CMY-2 ([@B10]). Recently, it was also described in clinical isolates of *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Enterobacter cloacae*, and *Serratia marcescens* ([@B3]; [@B6]; [@B5]; [@B20]).

In this study, we have characterized the ESBL-producing clinical strains of *E. coli* isolated between October 2008 and June 2012 in three hospitals in Western Algeria and determined the prevalence of 16S rRNA methylase genes among them.

Materials and Methods {#s1}
=====================

Bacterial Strains
-----------------

Two hundred and thirty-nine isolates of *E. coli* collected between October 2008 and June 2012 from three different hospitals located in North-Western Algeria (Tlemcen, Sidi Bel Abbes and Oran) were included. Two hundred and thirty-seven strains were isolated from patients admitted to the intensive care unit (ICU), surgery and neurosurgery wards. Two isolates have been recovered from hospital environment. Identification was performed using the API 20E system (BioMerieux) and/or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).

Antibiotic Susceptibility Testing
---------------------------------

Twenty three antibiotics (Bio-Rad) were tested (**Table [1](#T1){ref-type="table"}**). Antibiotic susceptibility testing was determined by disk diffusion method and the minimum inhibitory concentration (MICs) of colistin was determined by a dilution method in Mueller-Hinton (MH) broth (Bio-Rad) as described by the European Committee on Antimicrobial Susceptibility Testing^[1](#fn01){ref-type="fn"}^. Detection of ESBL production was performed by double disk synergy test ([@B19]).

###### 

Antimicrobial resistance of extended-spectrum-β-lactamases producing *Escherichia coli* isolated from three hospitals in Algeria.

  Antimicrobial agents             Resistance rate (%)                 
  -------------------------------- --------------------- ------ ------ ------
  Amoxicillin                      100                   100    100    100
  Amoxicillin--clavulanic acid     82.8                  92.3   42.1   73.1
  Ticarcillin                      100                   100    100    100
  Ticarcillin--clavulanic acid     97.1                  100    89.5   95.5
  Piperacillin                     100                   100    100    100
  Piperacillin--tazobactam         40                    15.4   0      23.9
  Ertapenem                        0                     0      0      0
  Imipenem                         0                     0      0      0
  Cefoxitin                        40                    38.5   26.3   35.8
  Cefotaxime                       100                   100    94.7   98.5
  Ceftazidime                      91.4                  92.3   84.2   89.5
  Cefepime                         100                   92.3   89.5   95.5
  Aztreonam                        100                   100    100    100
  Kanamicin                        60                    46.1   57.9   56.7
  Gentamicin                       77.1                  76.9   63.2   73.1
  Tobramycin                       77.1                  76.9   63.2   73.1
  Amikacin                         25.71                 7.7    15.8   19.4
  Netilmicin                       48.6                  61.5   57.9   53.7
  Nalidixic acid                   68.6                  53.8   89.5   71.6
  Ofloxacin                        68.6                  61.5   89.5   73.1
  Ciprofloxacin                    68.6                  61.5   84.2   71.6
  Colistin                         0                     0      0      0
  Trimethoprim--Sulfamethoxazole   80                    84.6   57.9   74.6

Bacterial DNA Preparation, Gene Amplification, and Sequencing
-------------------------------------------------------------

Bacterial DNA preparation, gene amplification, sequencing, and nucleotide sequence analysis were performed as previously described ([@B29]). The primers used for the PCRs are listed in **Table [2](#T2){ref-type="table"}**. All the isolates were analyzed for the presence of *bla*~CTX-M~, *bla*~TEM~, and *bla*~SHV~. The resistant strains to all aminoglycosides tested were further analyzed for the presence of *armA* and *rmtB*.

###### 

Primers used for PCRs.

  Amplified DNA          Primer         Oligonucleotide sequence (5′--3′)
  ---------------------- -------------- -----------------------------------
                         TEM--F~1~      ATAAAATTCTTGAAGACGAAA
  *bla*~TEM~             TEM--F         CTTATTCCCTTTTTTGCGGC
                         TEM--R         GGTCTGACAGTTACCAATGC
  *bla*~SHV~             SHV--F         GGGTTATTCTTATTTGTCGC
                         SHV--R         GTTAGCGTTGCCAGTGCTCG
  *bla*~CTX-M~           CTX-M--F       ATGTGCAGYACCAGTAA
                         CTX-M--R       ACCGCRATATCRTTGGT
  *bla*~CTX-M~ group 1   CTX-M-gr1--F   TCGTCTCTTCCAGA
                         CTX-M-gr1--R   CCGTTTCCGCTATTA
  *bla*~CTX-M~ group 9   CTX-M-gr9--F   ATGGTGACAAAGAGAGTGCA
                         CTX-M-gr9--R   ACAGCCCTTCGGCGATGATT
  *armA*                 *armA*-F       GTGCGAAAACAGTCGTAG
                         *armA*-R       GAAGTCAGGATACACCAG
  *rmtB*                 *rmtB*-F       GAGACACCGATGAACATC
                         *rmtB*-R       CCTTCTGATTGGCTTATC

Genotyping of the Isolates Producing 16S rRNA Methylase
-------------------------------------------------------

The strains were submitted to genotypic analysis by Pulsed-Field Gel Electrophoresis (PFGE) and Multilocus sequence typing (MLST). PFGE was performed following DNA digestion by *Xba*I as already described ([@B26]). Restriction patterns were interpreted according to Tenover's criteria ([@B30]), and the isolates have been classified into different pulsotypes. Pulsotypes were compared by calculation of the Dice correlation coefficient with DendroUPGMA software^[2](#fn02){ref-type="fn"}^ and were clustered into a dendrogram by UPGMA. Strains were defined as having a clonal relationship at a criterium of 85% similarity ([@B14]). MLST was performed using seven conserved housekeeping genes of *E. coli* (*adk, fumC, gyrB, icd, mdh, purA*, and *recA*) as previously described ([@B32]). The sequences types were determined by referring to the open-source software freely available at MLST Databases at the ERI, University College Cork website^[3](#fn03){ref-type="fn"}^.

Mating Experiments and Plasmids Analysis
----------------------------------------

Mating experiments to attempt to transfer resistance genes were carried out using rifampicin resistant *E. coli* K-12 C600 recipient strain as described previously ([@B13]). Transconjugants were selected on Drigalski agar plates containing amikacin (4 mg/L), gentamicin (4 mg/L), and rifampicin (200 mg/L), on Drigalski agar plates containing cefotaxime (4 mg/L) and rifampicin (200 mg/L), on Drigalski agar plates containing gentamicin (4 mg/L) and rifampicin (200 mg/L) and on Drigalski agar plates containing amikacin (30 mg/L) and rifampicin (200 mg/L).

Identification of plasmids by PCR-based replicon typing was performed on the donor strains and their transconjugants as described previously ([@B12]). Plasmid sizes were determined by digestion of whole-genome DNA with S1 endonuclease to linearize the plasmids and PFGE to separate them. Plasmids obtained were transferred to nylon membranes and hybridized with digoxigenin-labeled specific probes \[*bla*~CTX-M~ group 1, *bla*~TEM~, *armA*, *rmtB*, and replicon groups (IncL/M, IncFIA, IncFIB, and IncN)\] ([@B4]).

Results
=======

ESBL Producers
--------------

Sixty-seven ESBL-producing isolates have been detected: 35 from Tlemcen hospital, 13 from Sidi Bel Abbes hospital and 19 from Oran hospital. Isolates were mainly recovered from ICU (58.2%), followed by 26.9% from surgery department. Eighteen strains (26.9%) were recovered from wound pus, 17 (25.4%) from tracheal aspirate, 17 (25.4%) from urine and urinary catheters, 7 (10.4%) from rectal swabs, 4 (6%) from bedsores, 1 (1.5%) from catheter, 1 (1.5%) from gastric tube, and 2 (3%) from hospital environment. Among these strains 64 isolates (95.5%) carried *bla*~CTX-M~ (52 *bla*~CTX-M-15~, 5 *bla*~CTX-M-3~, 5 *bla*~CTX-M-1~, 2 *bla*~CTX-M-14~), while 2 carried *bla*~SHV-12~ and 1 *bla*~TEM-167~.

All the ESBL-producing isolates remained susceptible to imipenem, ertapenem, and colistin and most of them to piperacillin-tazobactam (76%), cefoxitin (64.2%), and amikacin (80.6%). However most of the strains were resistant to all other antibiotics tested (\>53%) (**Table [1](#T1){ref-type="table"}**).

Characterization of 16S rRNA Methylase-Producers (**Table [3](#T3){ref-type="table"}**; Supplementary Figure [S1](#SM1){ref-type="supplementary-material"})
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Twelve isolates were resistant to all aminoglycosides tested of which four strains harbored *armA* and 8 *rmtB*. *ArmA* was detected among CTX-M-15, CTX-M-1, and TEM-167-producers whereas *rmtB* was detected only among CTX-M-15-producers (**Table [3](#T3){ref-type="table"}**). The eight RmtB-producing strains all originated from Tlemcen hospital belonged to pulsotype A and to ST 405. A wider diversity was observed among the four ArmA-producers that belonged to three different pulsotypes (B, C, and D) and three different ST: ST10 (one isolate from Sidi Bel Abbes hospital), ST167 (one from Tlemcen hospital), and ST117 (two isolates from Oran hospital).

###### 

Characteristics of the 16S rRNA methylase producing *E. coli* strains isolated in Tlemcen, Sidi Bel Abbes, and Oran hospitals, Algeria.

  Strain   Hospital         Ward           Isolation date   Sample              ESBL (plasmid)                                    16S rRNA methylase (plasmid)                PFGE pulsotypes   MLST
  -------- ---------------- -------------- ---------------- ------------------- ------------------------------------------------- ------------------------------------------- ----------------- -------------------
  T E62    Tlemcen          Neurosurgery   19/10/2008       Bedsore             *bla*~CTX-M-15~\[Inc L/M 55 kb (T+)^3^\]          *armA* \[same Inc L/M 55 kb (T+)\]          C                 ST 167 (CC ST 10)
  S E23    Sidi Bel Abbes   Neurosurgery   18/03/2010       Pus                 *bla*~CTX-M-15~\[Inc L/M 55 kb (T+)\]             *armA* \[same Inc L/M 55 kb (T+)\]          D                 ST 10 (CC ST 10)
  0 E11    Oran             ICU**^1^**     16/12/2010       Infected wound      *bla*~TEM-167~\[Inc N 40 kb (T+)\]                *armA*\[Inc FIA size nd^5^ (T+)\]           B                 ST 117
  0 E13    Oran             Neurosurgery   16/12/2010       Gastric tube        *bla*~CTXM-1~\[Inc N 40 kb (T+)\]                 *armA*\[Inc FIA size nd (T-)\]              B                 ST 117
  T E114   Tlemcen          ICU            01/04/2010       Tracheal aspirate   *bla*~CTX-M-15~\[Inc FIA About 100 kb (T-)^4^\]   *rmtB* \[same Inc FIA About 100 kb (T-)\]   A                 ST 405
  T E116   Tlemcen          ICU            02/05/2010       Rectal swab         *bla*~CTX-M-15~\[Inc I1 About 100 kb (T+)\]       *rmtB* \[Inc FIA About 85 kb(T+)\]          A                 ST 405
  T E117   Tlemcen          ICU            20/05/2010       Tracheal aspirate   *bla*~CTX-M-15~\[Inc I1 About 100 kb (T+)\]       *rmtB* \[Inc FIA About 85 kb (T+)\]         A                 ST 405
  T E118   Tlemcen          ICU            01/06/2010       Tracheal aspirate   *bla*~CTX-M-15~\[(Inc I1 About 100 kb (T+)\]      *rmtB* \[Inc FIA About 85 kb (T+)\]         A                 ST 405
  T E120   Tlemcen          ICU            06/01/2011       Tracheal aspirate   *bla*~CTX-M-15~\[Inc I1 About 100 kb (T+)\]       *rmtB* \[Inc FIA About 85 kb (T+)\]         A                 ST 405
  T E124   Tlemcen          ICU            27/02/2011       Rectal swab         *bla*~CTX-M-15~\[Inc FIA About 100 kb (T-)\]      *rmtB* \[same Inc FIA About 100 kb (T-)\]   A                 ST 405
  T E133   Tlemcen          ENT^2^         21/04/2011       Catheter            *bla*~CTX-M-15~\[Inc FIA About 100 kb (T-)\]      *rmtB* \[same Inc FIA About 100 kb (T-)\]   A                 ST 405
  T E134   Tlemcen          ICU            26/04/2011       Urine               *bla*~CTX-M-15~\[Inc FIA About 100 kb (T-)\]      *rmtB* \[same Inc FIA About 100 kb (T-)\]   A                 ST 405

1

ICU, intensif care unit.

2

ENT, ear nose throat surgery.

3

T+, obtention of transconjugant.

4

T-, no transconjugant.

5

nd, non determined.

In the eight isolates, *rmtB* was located on a IncFIA plasmid. In four cases *bla*~CTX-M-15~ was located on the same plasmid while it was located on a IncI1 plasmid in the other four cases. IncFIA was transferred only in the presence of IncI1. *armA* was located either on a transferable IncL/M plasmid (with *bla*~CTX-M-15~) or on a IncFIA plasmid (in these two cases *bla*~CTX-M-1~ or *bla*~TEM-167~ were located on a IncN plasmid).

Discussion
==========

Our results are in accord with previous studies and confirm that CTX-M-15 is the predominant ESBL encountered among *E. coli* in Algerian hospitals ([@B28]; [@B2]). The same situation is also observed in Tunisia ([@B21]) and Morocco ([@B17]) illustrating the large spread of CTX-M-15-producing *E. coli* in the north African countries. Nevertheless, the CTX-M-1, CTX-M-14, SHV-12, and TEM-167 ESBLs also detected in our study had never been reported to date among *E. coli* strains in Algeria. There is a single description of CTX-M-14-producing *S. enterica* collected from Draa-El-Mizan hospital, east of Algeria ([@B18]) whereas SHV-12 has already been detected in clinical isolates of *K. pneumoniae* and *E. cloacae* in Algeria ([@B1]). There is no description of TEM-167 to date, only *bla*~TEM-167~ is available in GenBank (FJ360884).

Our study further highlights the emergence of 16S rRNA methylase enzymes among ESBL-producing *E. coli* strains in the west of Algeria. Among our collection, the prevalence rate of 16S rRNA methylase determinants was 18%, which is very high compared to those reported in Japan (0.03%) ([@B35]), in Turkey (0.7%) ([@B8]), in France (1.3%) ([@B7]), and in China (10%) ([@B34]). The detection of RmtB-producing *E. coli* is an interesting finding of our study. Indeed the RmtB enzyme has never been reported in Algeria. The eight isolates producing RmtB were genotypically related and belonged to ST405. Interestingly ST405 associated or not with production of CTX-M-15 ESBL is increasingly reported worldwide and belongs to the high-risk clones in the dissemination of antibiotic resistance ([@B33]). The association of *bla*~CTX-M-15~ and *rmtB* on a conjugative plasmid (also carrying the plasmid-mediated fluoroquinolone eﬄux pump gene *qepA*) in one ST405 *E. coli* isolate has been reported in the United States ([@B31]) but the plasmid was not typed by PCR-based replicon.

All RmtB-producers have been recovered in Tlemcen Hospital and seven of them were collected in ICU suggesting patient cross contamination in this ward.

Therefore there is a need to reinforce the compliance of health-care workers with the infection control measures. The epidemiological results concerning ArmA-producers is quite different: the four isolates recovered in three hospitals in Western Algeria belonged to three different pulsotypes suggesting horizontal spread of the resistance determinants among *E. coli*. There are several reports of ArmA-producers among different species of *Enterobacteriaceae* and also *A. baumannii* from Algerian Hospitals ([@B9]; [@B23], [@B22]; [@B10]; [@B3]; [@B6]; [@B5]; [@B20]). The production of 16S rRNA methylase together with the production of ESBL observed in our study (RmtB plus CTX-M-15 or ArmA plus CTX-M-15) corresponds to an emerging and threatening combination reported worldwide ([@B9]; [@B20]). To our best knowledge two combinations detected in our study were not reported before: ArmA plus CTX-M-1 and ArmA plus TEM-167 in two isolates clonally related (OE11 and OE13) recovered simultaneously from Oran's hospital.

Our data indicated that the diversity of ESBL among *E. coli* is growing in Algerian hospitals (CTX-M-1, CTX-M-14, CTX-M-15, TEM-167, and SHV-12) and that new mechanisms are emerging (16S rRNA methylases). In our study 11 out of 12 isolates that co-produced ESBL and methylase were resistant to all antibiotics tested except carbapenems and colistin, making of them the only available therapeutic option for these strains. Therefore the public health impact is potentially important.

Conclusion
==========

There is a need for implementation of antimicrobial stewardship programs in Algerian hospitals to make the best use of the available antibiotics and to avoid as much as possible the unreasonable use of broad-spectrum molecules leading to the emergence of resistant isolates. Also strict control measures have to be elaborated to avoid the spread of multiresistant organisms such as those described here that co-produced ESBL and 16S rRNA methylase.
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